These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 16421163

  • 1. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
    Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD.
    Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
    [Abstract] [Full Text] [Related]

  • 2. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin.
    Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD.
    Kidney Int; 2005 Jul; 68(1):246-55. PubMed ID: 15954914
    [Abstract] [Full Text] [Related]

  • 3. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.
    Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M.
    Prostaglandins Leukot Essent Fatty Acids; 2005 Mar; 72(3):203-9. PubMed ID: 15664305
    [Abstract] [Full Text] [Related]

  • 4. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
    Wan DH, Fan P, Bai H, Song Q, Liu HW.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
    [Abstract] [Full Text] [Related]

  • 5. Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles.
    Mitsios JV, Vini MP, Stengel D, Ninio E, Tselepis AD.
    Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1907-13. PubMed ID: 16728656
    [Abstract] [Full Text] [Related]

  • 6. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD.
    Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasiliou EC, Tselepis AD.
    Am J Kidney Dis; 2006 Aug; 48(2):242-9. PubMed ID: 16860190
    [Abstract] [Full Text] [Related]

  • 7. Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.
    Caini P, Guerra CT, Giannini C, Giannelli F, Gragnani L, Petrarca A, Solazzo V, Monti M, Laffi G, Zignego AL.
    J Viral Hepat; 2007 Jan; 14(1):22-8. PubMed ID: 17212640
    [Abstract] [Full Text] [Related]

  • 8. Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes.
    Gomes MB, Cobas RA, Nunes E, Nery M, Castro-Faria-Neto HC, Tibiriçá E.
    Prostaglandins Other Lipid Mediat; 2008 Dec; 87(1-4):42-6. PubMed ID: 18718550
    [Abstract] [Full Text] [Related]

  • 9. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effect.
    Milionis HJ, Tambaki AP, Kanioglou CN, Elisaf MS, Tselepis AD, Tsatsoulis A.
    Thyroid; 2005 May; 15(5):455-60. PubMed ID: 15929667
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U, Ba16285 Study Investigators.
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [Abstract] [Full Text] [Related]

  • 11. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
    Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC.
    Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
    [Abstract] [Full Text] [Related]

  • 12. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress.
    Noto H, Hara M, Karasawa K, Iso-O N, Satoh H, Togo M, Hashimoto Y, Yamada Y, Kosaka T, Kawamura M, Kimura S, Tsukamoto K.
    Arterioscler Thromb Vasc Biol; 2003 May 01; 23(5):829-35. PubMed ID: 12649088
    [Abstract] [Full Text] [Related]

  • 13. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
    Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, Taccola D, Donadio C, Tramonti G, Innocenti M, Casto G, Consani C, Sbragia G, Franzoni F, Galetta F, Panicucci E, Barsotti G.
    Nephrol Dial Transplant; 2006 Feb 01; 21(2):337-44. PubMed ID: 16249194
    [Abstract] [Full Text] [Related]

  • 14. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May 01; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 15. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia.
    Brites FD, Verona J, Schreier LE, Fruchart JC, Castro GR, Wikinski RL.
    Arch Med Res; 2004 May 01; 35(3):235-40. PubMed ID: 15163466
    [Abstract] [Full Text] [Related]

  • 16. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase.
    Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD.
    Cardiovasc Res; 2004 Jul 01; 63(1):130-8. PubMed ID: 15194469
    [Abstract] [Full Text] [Related]

  • 17. Maternal and fetal plasma platelet-activating factor acetylhydrolase activity and distribution in pre-eclampsia.
    Fan P, Liu XH, He GL, Zhang S, Zhang JX, Bai H.
    Pediatr Res; 2012 Oct 01; 72(4):426-31. PubMed ID: 22797139
    [Abstract] [Full Text] [Related]

  • 18. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, Darapladib Investigators.
    J Am Coll Cardiol; 2008 Apr 29; 51(17):1632-41. PubMed ID: 18436114
    [Abstract] [Full Text] [Related]

  • 19. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease.
    Ninio E, Tregouet D, Carrier JL, Stengel D, Bickel C, Perret C, Rupprecht HJ, Cambien F, Blankenberg S, Tiret L.
    Hum Mol Genet; 2004 Jul 01; 13(13):1341-51. PubMed ID: 15115767
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB, Dowell JA, Pratt RD.
    Clin Ther; 2007 Jul 01; 29(7):1368-80. PubMed ID: 17825688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.